OMass’s molecule is vying to become an alternative to a Neurocrine Biosciences drug that is currently the only FDA-approved therapy for congenital adrenal hyperplasia. But Vertex Pharmaceuticals could also compete with a drug candidate from a recent acquisition.
Allswell's seed round was led by Rethink Impact, and included participation from Magnify Ventures, Ulu Ventures and Hopelab Ventures, joining existing investors Techstars and Amboy Street Ventures.
Healthcare decision-makers, especially at pharmaceutical companies, must prioritize patient input. Data collected from social media listening is a significant step in the right direction.
This is not a discovery problem. It is a market entry and access problem, and it is far more tractable than the pipeline crisis we spend most of our attention on.
Health care routinely recommends movement without providing assessment, dosage, progression, and follow-up that turn good advice into usable care.
UPMC Enterprises is making a strategic investment in VeloSource with plans to further develop its AI-enabled staffing management platform.
Epic will launch a tool in summer 2027 to help patients compare prescription cash prices and insurance costs across pharmacies.
Healthcare payments are no longer about transactions. It’s about controlling the revenue cycle. And increasingly, that control is not sitting with ISOs.
City Therapeutics’ lead RNA interference therapy could become an alternative to blockbuster-selling anticoagulants. The company’s technology for designing RNAi drugs and delivering them to tissues throughout the body has already led to partnerships with Bausch + Lomb in eye diseases and Biogen in central nervous system disorders.
There is no single solution to the cross-subsidization problem. But here are some strategic actions that can make a health system’s economics more sustainable.
The connected, agent-ready enterprise is the model that wins, where compliance and intelligence operate together.
Rosarium Health partnered with Anthem Medi-Cal to provide home safety modifications for eligible members.
Enterprise EHR boosts scalability, interoperability, and governance for large healthcare systems.
Iambic Therapeutics, an AI-enabled biotech company, will apply the IPO proceeds toward clinical development of its pipeline of internally discovered and wholly owned cancer drugs. Iambic also has R&D alliances with companies such as Bayer and AbbVie.
What is needed is a fundamentally different operating model for primary care, one designed around continuous engagement rather than episodic encounters.
Panelists in the webinar, sponsored by Inovalon, will explore how near real-time surveillance, smart risk prioritization, and closed-loop intervention are shifting stewardship programs to proactive, technology-enabled decision-making that lets pharmacists work at the top of their license.
HealthTap launched a virtual care program to support sleep equipment suppliers and patients using PAP therapy.
Ultragenyx Pharmaceutical sold two priority review vouchers, each from an FDA approval of a gene therapy. Both therapies came from business deals and proceeds from the voucher sales put Ultragenyx in a better financial position to pursue yet another deal for a rare disease asset.